Core B: Biospecimen and Pathology Core

核心 B：生物样本和病理学核心

• 批准号: 9767047
• 负责人: Daniel Visscher
• 金额: $ 27.96万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9767047
• 关键词: Aliquot; Antibodies; Atypia; Benign; Biological Assay; Biological Markers; Biopsy; Blood specimen; Breast; Breast Diseases; Clinic; Clinical; Combined Modality Therapy; Cystatins; DNA; Diagnosis; Equipment; Estrogen Receptor beta; Evaluation; Evaluation Research; Formalin; Freezing; Frozen Sections; Genomic DNA; Genomics; Histologic; Histology; Hospitals; Image Analysis; Immunoglobulin G; Immunohistochemistry; Infrastructure; Location; Malignant Neoplasms; Mammaplasty; Mammary Gland Parenchyma; Measures; Mus; Paraffin; Paraffin Embedding; Pathologic; Pathology; Patients; Phase I Clinical Trials; Phase II Clinical Trials; Process; RNA; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Risk Reduction; Sampling; Serum; Services; Slide; Specimen; Stains; Standardization; Technology; Tissue Microarray; Tissue Sample; Tissues; Translational Research; Update; Whole Blood; Work; Xenograft procedure; base; cohort; digital imaging; experience; malignant breast neoplasm; service utilization; translational cancer research; translational study; tumor

Project Summary/Abstract The primary objective of the Biospecimen and Pathology Core of the Mayo Clinic Breast Cancer SPORE is to provide an effective centralized resource that will accrue clinically derived breast tissue samples and characterize them for standard clinical pathological parameters (e.g., stage, biomarker status, diagnosis) in order to create banks and cohorts for research purposes. Samples collected will include fresh frozen and formalin fixed paraffin embedded cancers, benign breast disease tissues, and “normal” mammoplasty/risk reduction specimens, as well as whole blood. The Biospecimen and Pathology Core will also perform expert pathological evaluation of research related histopathological parameters (e.g., atypia in benign breast disease and subclassification of TN tumors) and interpretation of immunostains relevant to SPORE projects (e.g., ERβ). The Core will support translational studies by selecting appropriate samples for analysis, assisting with application of special technologies to SPORE projects (e.g., image analysis), and assessing antibody optimizations (e.g., phospho-ERβ, cystatin 1/2/4, cystatin 5, and phospho-smad2/3). Immunostain quantification evaluation using digitized image analysis will be developed and standardized by the CORE. The Biospecimen and Pathology Core will coordinate with the Mayo Biospecimen Accessioning and Processing Shared Resource to store cryospecimens and to process blood samples to provide genomic DNA and serum aliquots; it will collaborate with the Mayo Pathology Research Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state of the art equipment.

项目摘要/摘要 蛋黄酱诊所乳腺癌孢子的生物测量和病理核心的主要目标是 提供有效的集中资源，将获得临床衍生的乳腺组织样品和 将它们描述为标准的临床病理参数（例如，阶段，生物标志物状态，诊断） 为了创建用于研究目的的银行和同伙。收集的样品将包括新鲜的冷冻和 福尔马林固定石蜡嵌入癌症，良性乳腺病组织和“正常”乳腺成形术/风险 还原标本以及全血。生物测量和病理核心也将执行专家 研究相关的组织病理学参数的病理评估（例如，良性乳房疾病中的亚典目的 和TN肿瘤的亚分类）和与孢子项目相关的免疫抑制剂的解释（例如， ERβ）。核心将通过选择适当的样本进行分析来支持翻译研究，并协助 特殊技术在孢子项目中的应用（例如，图像分析）和评估抗体 优化（例如，磷酸-ERβ，半胱氨酸蛋白酶1/2/4，Cystatin 5和Phosho-Smad2/3）。免疫抑制剂 使用数字化图像分析的数量评估将由核心开发和标准化。这 生物测量和病理学核心将与蛋黄酱生物循环的登录和加工协调 共享资源以存储冰冻细胞并处理血液样本以提供基因组DNA和串行 等分试样；它将与Mayo病理研究共享资源合作，以提供组织学和其他 基于组织的服务，包括石蜡和冷冻切片，免疫组织化学，组织微阵列 构造和数字成像。与现有基础架构（例如这些共享资源）紧密合作 最大程度地减少服务的冗余，并利用现有的经验和最先进的设备。